绝经后骨质疏松症药物治疗的现状与思考
发布时间：2018-10-24 07:20
【摘要】：绝经后骨质疏松症(postmenopausal osteoporosis,PMOP)是指绝经后妇女体内雌激素水平下降,骨形成和骨吸收失耦连,导致以骨量减少和骨组织显微结构破坏为特征的一种全身代谢性骨病,是绝经后妇女的常见病及多发病。随着我国人口老龄化,绝经后骨质疏松症以其高发病率、高致残率逐渐成为严峻的公共卫生及社会问题。临床治疗绝经后骨质疏松症的药物以西药为主,中药为辅,但西药严重的毒副作用和中药作用机制的不明确都制约着其进一步的推广。目前,随着骨代谢机制的进一步明确和相关诊疗技术的突破,临床用药有了新的进展。本文以临床药物治疗为出发点,从西药、中药两个方面入手,通过查阅国内外近期相关文献,对西药类(基础药物,抗骨吸收药物、促进骨形成药物、双重药理作用药物)和中药类(单味中药、中药提取物、复方制剂)的临床使用现状进行归纳总结,同时提出笔者对绝经后骨质疏松症药物治疗现状的思考。
[Abstract]:Postmenopausal osteoporosis (postmenopausal osteoporosis,PMOP) is a systemic metabolic bone disease characterized by decreased estrogen levels, bone formation and bone resorption decoupling in postmenopausal women, characterized by reduced bone mass and destruction of bone microstructure. It is a common and frequent disease in postmenopausal women. With the aging of population, postmenopausal osteoporosis has become a serious public health and social problem due to its high morbidity and high disability rate. Western medicine is the main drug in the treatment of postmenopausal osteoporosis, while Chinese medicine is supplementary. However, the serious side effects of western medicine and the unclear mechanism of action of traditional Chinese medicine restrict its further promotion. At present, with the further clarification of bone metabolism mechanism and breakthrough of related diagnosis and treatment technology, clinical drug use has made new progress. Starting with clinical drug therapy, starting with western medicine and traditional Chinese medicine, and referring to the recent literature at home and abroad, the article discusses the western medicine (basic drugs, anti-bone absorption drugs, promoting bone formation drugs). The present situation of clinical use of traditional Chinese medicine (single Chinese medicine, extract of traditional Chinese medicine, compound preparation) was summarized, and the author's thoughts on drug treatment of postmenopausal osteoporosis were put forward.
【作者单位】： 福建中医药大学;
【基金】：国家自然科学基金资助项目(81574003) 福建省科技厅引导性项目(2015Y0069) 陈可冀中西医结合发展基金资助(CKJ201411)
【分类号】：R580
，
本文编号：2290705
[Abstract]:Postmenopausal osteoporosis (postmenopausal osteoporosis,PMOP) is a systemic metabolic bone disease characterized by decreased estrogen levels, bone formation and bone resorption decoupling in postmenopausal women, characterized by reduced bone mass and destruction of bone microstructure. It is a common and frequent disease in postmenopausal women. With the aging of population, postmenopausal osteoporosis has become a serious public health and social problem due to its high morbidity and high disability rate. Western medicine is the main drug in the treatment of postmenopausal osteoporosis, while Chinese medicine is supplementary. However, the serious side effects of western medicine and the unclear mechanism of action of traditional Chinese medicine restrict its further promotion. At present, with the further clarification of bone metabolism mechanism and breakthrough of related diagnosis and treatment technology, clinical drug use has made new progress. Starting with clinical drug therapy, starting with western medicine and traditional Chinese medicine, and referring to the recent literature at home and abroad, the article discusses the western medicine (basic drugs, anti-bone absorption drugs, promoting bone formation drugs). The present situation of clinical use of traditional Chinese medicine (single Chinese medicine, extract of traditional Chinese medicine, compound preparation) was summarized, and the author's thoughts on drug treatment of postmenopausal osteoporosis were put forward.
【作者单位】： 福建中医药大学;
【基金】：国家自然科学基金资助项目(81574003) 福建省科技厅引导性项目(2015Y0069) 陈可冀中西医结合发展基金资助(CKJ201411)
【分类号】：R580
，
本文编号：2290705
本文链接：https://www.wllwen.com/yixuelunwen/nfm/2290705.html
最近更新
教材专著
